Literature DB >> 19934312

MBP-1 inhibits breast cancer growth and metastasis in immunocompetent mice.

Tatsuo Kanda1, Amit Raychoudhuri, Robert Steele, John E Sagartz, Cheri West, Ratna B Ray.   

Abstract

Breast cancer is the leading cause of cancer death among women. We have shown previously an antiproliferative effect of MBP-1 on several human cancer cells. In this study, we have examined the potential of MBP-1 as a gene therapeutic candidate in regression of breast cancer growth and metastasis in an immunocompetent mouse model. For this, we have used a mouse breast cancer cell line (EO771) and syngeneic C57BL/6 mice. EO771 cells were implanted into the mammary fat pad of C57BL/6 mice. Replication-deficient recombinant adenovirus expressing MBP-1 was administered intratumorally to determine gene therapeutic potential. The results showed a significant regression of primary and distant (lung) tumor growth. Animals exhibited prolonged survival on treatment with MBP-1 compared with the control group (dl312). Subsequent studies suggested that MBP-1 inhibits matrix metalloproteinase expression in human breast cancer cells. Cells transduced with MBP-1 displayed inhibition of migration in a wound-healing assay. The conditioned medium from MBP-1-transduced cells blocked in vitro tube formation assay and inhibited expression of several angiogenic molecules. Taken together, our study shows that MBP-1 acts as a double-edged sword by inhibiting primary and metastatic tumor growth and modulating matrix metalloproteinase expression with a therapeutic potential against breast cancer progression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19934312     DOI: 10.1158/0008-5472.CAN-09-2974

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  MBP-1 upregulates miR-29b that represses Mcl-1, collagens, and matrix-metalloproteinase-2 in prostate cancer cells.

Authors:  Robert Steele; Justin L Mott; Ratna B Ray
Journal:  Genes Cancer       Date:  2010-04-01

2.  Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2.

Authors:  Joao Incio; Jennifer A Ligibel; Daniel T McManus; Priya Suboj; Keehoon Jung; Kosuke Kawaguchi; Matthias Pinter; Suboj Babykutty; Shan M Chin; Trupti D Vardam; Yuhui Huang; Nuh N Rahbari; Sylvie Roberge; Dannie Wang; Igor L Gomes-Santos; Stefan B Puchner; Christopher L Schlett; Udo Hoffmman; Marek Ancukiewicz; Sara M Tolaney; Ian E Krop; Dan G Duda; Yves Boucher; Dai Fukumura; Rakesh K Jain
Journal:  Sci Transl Med       Date:  2018-03-14       Impact factor: 17.956

3.  Myc promoter-binding protein-1 (MBP-1) is a novel potential prognostic marker in invasive ductal breast carcinoma.

Authors:  Mariavera Lo Presti; Arianna Ferro; Flavia Contino; Claudia Mazzarella; Silvia Sbacchi; Elena Roz; Carmelo Lupo; Giovanni Perconti; Agata Giallongo; Paola Migliorini; Antonio Marrazzo; Salvatore Feo
Journal:  PLoS One       Date:  2010-09-23       Impact factor: 3.240

Review 4.  The Biological Significance and Regulatory Mechanism of c-Myc Binding Protein 1 (MBP-1).

Authors:  Zijin Liu; Aileen Zhang; Lamei Zheng; Abou-Fadel Johnathan; Jun Zhang; Genfa Zhang
Journal:  Int J Mol Sci       Date:  2018-12-04       Impact factor: 5.923

5.  Expression of Alpha-Enolase (ENO1), Myc Promoter-Binding Protein-1 (MBP-1) and Matrix Metalloproteinases (MMP-2 and MMP-9) Reflect the Nature and Aggressiveness of Breast Tumors.

Authors:  Patrizia Cancemi; Miriam Buttacavoli; Elena Roz; Salvatore Feo
Journal:  Int J Mol Sci       Date:  2019-08-14       Impact factor: 5.923

6.  HIF‑1α and MBP1 are associated with the progression of breast cancer cells by repressing β‑catenin transcription.

Authors:  Ying Zhuang; Xiang Li; Peng Zhan; Guoliang Pi; Gu Wen
Journal:  Oncol Rep       Date:  2022-07-07       Impact factor: 4.136

7.  Bitter melon reduces head and neck squamous cell carcinoma growth by targeting c-Met signaling.

Authors:  Ananthi Rajamoorthi; Shubham Shrivastava; Robert Steele; Pratibha Nerurkar; Juan G Gonzalez; Susan Crawford; Mark Varvares; Ratna B Ray
Journal:  PLoS One       Date:  2013-10-17       Impact factor: 3.240

8.  A function-blocking CD47 antibody suppresses stem cell and EGF signaling in triple-negative breast cancer.

Authors:  Sukhbir Kaur; Abdel G Elkahloun; Satya P Singh; Qing-Rong Chen; Daoud M Meerzaman; Timothy Song; Nidhi Manu; Weiwei Wu; Poonam Mannan; Susan H Garfield; David D Roberts
Journal:  Oncotarget       Date:  2016-03-01

Review 9.  EO771, is it a well-characterized cell line for mouse mammary cancer model? Limit and uncertainty.

Authors:  Augustin Le Naour; Adrien Rossary; Marie-Paule Vasson
Journal:  Cancer Med       Date:  2020-10-07       Impact factor: 4.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.